KR20170138574A - 항암 융합 폴리펩타이드 - Google Patents

항암 융합 폴리펩타이드 Download PDF

Info

Publication number
KR20170138574A
KR20170138574A KR1020177034820A KR20177034820A KR20170138574A KR 20170138574 A KR20170138574 A KR 20170138574A KR 1020177034820 A KR1020177034820 A KR 1020177034820A KR 20177034820 A KR20177034820 A KR 20177034820A KR 20170138574 A KR20170138574 A KR 20170138574A
Authority
KR
South Korea
Prior art keywords
ser
lys
leu
asp
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020177034820A
Other languages
English (en)
Korean (ko)
Inventor
말론 히너
크리스틴 로테
쉐인 올윌
라시다 시함 벨 아이바
울리히 뫼비우스
코리나 슐로서
토마스 진 호아킨
Original Assignee
피어이스 파마슈티컬즈 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피어이스 파마슈티컬즈 게엠베하 filed Critical 피어이스 파마슈티컬즈 게엠베하
Publication of KR20170138574A publication Critical patent/KR20170138574A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020177034820A 2015-05-04 2016-05-04 항암 융합 폴리펩타이드 Pending KR20170138574A (ko)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
EP15166179.0 2015-05-04
EP15166179 2015-05-04
EP15167917 2015-05-18
EP15167917.2 2015-05-18
EP15002702.7 2015-09-17
EP15002702 2015-09-17
EP15192870.2 2015-11-04
EP15192870 2015-11-04
EP16150705 2016-01-11
EP16150705.8 2016-01-11
EP16000862 2016-04-15
EP16000862.9 2016-04-15
PCT/EP2016/060041 WO2016177802A1 (en) 2015-05-04 2016-05-04 Anti-cancer fusion polypeptide

Publications (1)

Publication Number Publication Date
KR20170138574A true KR20170138574A (ko) 2017-12-15

Family

ID=55948826

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177034820A Pending KR20170138574A (ko) 2015-05-04 2016-05-04 항암 융합 폴리펩타이드

Country Status (13)

Country Link
US (2) US10865250B2 (https=)
EP (2) EP3292148B1 (https=)
JP (1) JP6783797B2 (https=)
KR (1) KR20170138574A (https=)
CN (2) CN107636014B (https=)
AU (1) AU2016258977C1 (https=)
BR (1) BR112017020434A2 (https=)
CA (1) CA2980840A1 (https=)
MX (1) MX2017014083A (https=)
RU (1) RU2727165C2 (https=)
SG (1) SG11201708334RA (https=)
WO (1) WO2016177802A1 (https=)
ZA (1) ZA201705961B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3094650A2 (en) * 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multi-specific polypeptide useful for localized tumor immunomodulation
KR102734408B1 (ko) * 2015-05-04 2024-11-27 피어이스 파마슈티컬즈 게엠베하 Cd137에 특이적인 신규한 단백질
MX390894B (es) * 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
KR102664891B1 (ko) 2016-06-20 2024-05-13 에프-스타 테라퓨틱스 리미티드 Pd-l1 및 lag-3에 결합하는 결합 분자
KR20190022632A (ko) 2016-06-20 2019-03-06 에프-스타 베타 리미티드 Lag-3 결합 구성원
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
BR112019013189A2 (pt) * 2017-01-03 2019-12-10 Hoffmann La Roche moléculas de ligação ao antígeno biespecífica, polinucleotídeo, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica, composição farmacêutica, uso, métodos para inibir o crescimento de células tumorais em um indivíduo e para tratar o câncer ou uma doença infecciosa
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
WO2018134279A1 (en) * 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
IL268836B2 (en) 2017-02-24 2024-04-01 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019092452A1 (en) * 2017-11-13 2019-05-16 Crescendo Biologics Limited Molecules that bind to cd137 and psma
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019121906A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Specific pd-l1 binding sequences inserted in a ch3 domain
TWI841551B (zh) * 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
KR20200136949A (ko) 2018-03-26 2020-12-08 4에스체 악티엔게젤샤프트 암 치료를 위한 hdac 억제제 및 cd137 작용제를 포함하는 배합물
CR20200459A (es) 2018-04-13 2020-11-11 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
PL3820569T3 (pl) 2018-07-12 2025-07-14 Invox Pharma Limited Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
BR112021000282A2 (pt) 2018-07-12 2021-04-06 F-Star Beta Limited Moléculas de anticorpo que se ligam a cd137 e ox40
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
CA3100119A1 (en) * 2018-07-31 2020-02-06 Pieris Pharmaceuticals Gmbh Fusion protein specific for cd137 and pd-l1
CN112955221A (zh) * 2018-08-27 2021-06-11 皮里斯制药有限公司 包含cd137/her2双特异性试剂和pd-1轴抑制剂的组合疗法及其用途
MX2021010039A (es) * 2019-02-26 2021-09-21 Pieris Pharmaceuticals Gmbh Novedosas proteinas de fusion especificas para cd137 y gpc3.
AU2020253034A1 (en) * 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
WO2020208049A1 (en) 2019-04-12 2020-10-15 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising lipocalin muteins
US12240913B2 (en) 2019-07-26 2025-03-04 Abl Bio Inc. Anti-HER2/anti-4-1BB bispecific antibody and use thereof
JP2023502876A (ja) * 2019-11-04 2023-01-26 ピエリス ファーマシューティカルズ ゲーエムベーハー がんの治療のためのｈｅｒ２／４－１ｂｂ二重特異性融合タンパク質
CA3169910A1 (en) * 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Anti-cd137 constructs, multispecific antibody and uses thereof
KR20230042524A (ko) * 2020-08-07 2023-03-28 주식회사 유틸렉스 항-her2 / 항-4-1bb 이중특이적 항체 및 이의 용도
US20230366884A1 (en) 2020-09-18 2023-11-16 Pieris Pharmaceuticals Gmbh Biomarker methods and uses
EP4281467A4 (en) * 2021-01-25 2024-12-04 Yuhan Corporation Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody
CN117355319A (zh) 2021-03-23 2024-01-05 皮里斯制药有限责任公司 用于癌症治疗的her2/4-1bb双特异性融合蛋白
WO2022200478A1 (en) 2021-03-24 2022-09-29 Pieris Pharmaceuticals Gmbh Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor
KR20230171465A (ko) 2021-04-22 2023-12-20 아스텔라스세이야쿠 가부시키가이샤 항cldn4-항cd137 이중특이성 항체
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
KR20250075621A (ko) 2022-09-20 2025-05-28 바이오세우스 인크. 항체 및 종양 저항에서의 이의 용도
EP4606384A1 (en) * 2022-10-19 2025-08-27 Astellas Pharma, Inc. Use of anti-cldn4-anti-cd137 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
ES2245780T3 (es) 1994-05-18 2006-01-16 Nektar Therapeutics Metodos y composiciones para la formulacion de interferones como un polvo seco.
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
US20030171551A1 (en) 1997-01-31 2003-09-11 Joseph D. Rosenblatt Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
AU8899298A (en) 1997-08-06 1999-03-01 Zymogenetics Inc. Lipocalin homologs
US20140080177A1 (en) 1997-09-26 2014-03-20 Pieris Ag Anticalins
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
CZ298681B6 (cs) 1998-06-08 2007-12-19 F. Hoffmann-La Roche Ag Lécivo pro lécení infekcí chronické hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
CA2343917A1 (en) 1998-10-19 2000-04-27 Ariad Gene Therapeutics, Inc. Materials and methods involving conditional retention domains
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
US8313924B2 (en) * 2006-08-01 2012-11-20 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
CA2702611A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Immunoassays and kits for the detection of ngal
AU2008328726B2 (en) 2007-11-30 2014-06-12 Glaxo Group Limited Antigen-binding constructs
WO2009114110A1 (en) 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
JP5711118B2 (ja) 2008-06-24 2015-04-30 テクニッシュ ウニヴェルジテート ミュンヘン 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
US20110305694A1 (en) 2009-02-24 2011-12-15 Paul Andrew Hamblin Multivalent and/or multispecific rankl-binding constructs
KR20140014405A (ko) 2009-05-28 2014-02-06 글락소 그룹 리미티드 안구 질병을 치료하거나 예방하는데 사용되는 ｔｎｆ-알파 길항제 및 ｖｅｇｆ 길항제의 조합물
JP2013501033A (ja) 2009-08-05 2013-01-10 ピエリス アーゲー リポカリン突然変異タンパク質の制御放出製剤
BR112012013662B1 (pt) 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
CA3083324A1 (en) * 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
NZ606584A (en) 2010-08-16 2014-10-31 Pieris Ag Binding proteins for hepcidin
US9260492B2 (en) 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
EP2646552B1 (en) 2010-12-02 2017-07-05 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for ctla-4
CN110563850A (zh) * 2012-04-30 2019-12-13 比奥孔有限公司 靶向/免疫调节性融合蛋白及其制造方法
EP3094650A2 (en) * 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multi-specific polypeptide useful for localized tumor immunomodulation
WO2016109415A1 (en) * 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
US11382963B2 (en) 2015-01-12 2022-07-12 Pieris Pharmaceuticals Gmbh Engineered T cells and uses therefor
JP6839087B2 (ja) 2015-01-28 2021-03-03 ピエリス ファーマシューティカルズ ゲーエムベーハー 血管新生に特異的な新規のタンパク質
TN2017000348A1 (en) 2015-02-18 2019-01-16 Sanofi Sa Novel proteins specific for pyoverdine and pyochelin
KR102734408B1 (ko) 2015-05-04 2024-11-27 피어이스 파마슈티컬즈 게엠베하 Cd137에 특이적인 신규한 단백질
AU2016262838B2 (en) 2015-05-18 2020-10-08 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白

Also Published As

Publication number Publication date
EP3292148B1 (en) 2024-01-24
US20190010248A1 (en) 2019-01-10
RU2017135596A3 (https=) 2019-09-16
MX2017014083A (es) 2018-11-09
US10865250B2 (en) 2020-12-15
JP6783797B2 (ja) 2020-11-11
AU2016258977C1 (en) 2022-07-14
US20210198380A1 (en) 2021-07-01
CA2980840A1 (en) 2016-11-10
EP4378962A3 (en) 2024-07-31
BR112017020434A2 (pt) 2018-06-26
CN114316067A (zh) 2022-04-12
AU2016258977A1 (en) 2017-11-30
RU2017135596A (ru) 2019-06-04
JP2018515085A (ja) 2018-06-14
EP3292148A1 (en) 2018-03-14
RU2727165C2 (ru) 2020-07-21
EP4378962A2 (en) 2024-06-05
SG11201708334RA (en) 2017-11-29
HK1249526A1 (en) 2018-11-02
CN107636014B (zh) 2021-12-07
WO2016177802A1 (en) 2016-11-10
AU2016258977B2 (en) 2022-03-17
ZA201705961B (en) 2023-12-20
CN107636014A (zh) 2018-01-26

Similar Documents

Publication Publication Date Title
KR20170138574A (ko) 항암 융합 폴리펩타이드
RU2754466C2 (ru) Слитый полипептид с противораковой активностью
RU2628699C2 (ru) Trail r2-специфические мультимерные скаффолды
CN107835820A (zh) 识别癌症特异性IL13Rα2的CAR T细胞
CN107683289A (zh) IL13RAα2结合剂和其在癌症治疗中的用途
KR20230065259A (ko) Il10 수용체 결합 분자 및 사용 방법
US20230366884A1 (en) Biomarker methods and uses
US20240166763A1 (en) Her2/4-1bb bispecific fusion proteins for the treatment of cancer
US20240166764A1 (en) Her2/4-1bb bispecific fusion proteins for the treatment of cancer
CN117247456A (zh) 靶向her2，pd-l1和vegf的三特异性抗体
JP2025532652A (ja) Ｃｄ１３７およびｃｄ２２８に特異的な新規融合タンパク質
HK1249526B (en) Anti-cancer fusion polypeptide

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171201

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210430

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230722

Patent event code: PE09021S01D

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240625